Sarepta Gene Therapy Setbacks

News

FDA asks Sarepta to stop shipping gene therapy

Sarepta Shares Drop as FDA Suspends Gene Therapy Trials for Muscular Dystrophy

Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) plunged 10% after the company disclosed that the U.S. Food and Drug Administration (FDA) has imposed a clinical hold on several of its gene therapy programs targeting limb girdle muscular dystrophy (LGMD).

Pharmaceutical Technology · 53m

Sarepta refuses to pull gene therapy despite FDA order

· 2d

Sarepta's Setback Deepens With Another Gene Therapy Fatality

Sarepta: Despite Restructuring, Downgrading To Sell After Latest Developments

The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm ...

4don MSN

Sarepta to cut 500 jobs, add black-box warning on gene therapy

Sarepta Therapeutics will cut 500 jobs and add a serious warning on the label of its muscle-disorder gene therapy Elevidys, the drugmaker said on Wednesday, following the recent deaths of two patients ...

MedCity News1y

Pfizer & Sarepta Gene Therapies Both Failed Phase 3, But Analysts ...

A Pfizer gene therapy for Duchenne muscular dystrophy failed its Phase 3 clinical trial. But analysts draw distinctions between that therapy and Sarepta Therapeutics’ Elevidys, which awaits an ...

Seeking Alpha6y

Sarepta Gains After Pfizer Suffers A Setback With Gene Therapy For DMD

Sarepta Gains After Pfizer Suffers A Setback With Gene Therapy For DMD Jul. 09, 2019 8:08 PM ET Sarepta Therapeutics, Inc. (SRPT) Stock PFE , SRPT 9 Comments 4 Likes Terry Chrisomalis ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results